Multidrug resistance is more than MDR1 activity
- 1 July 1995
- journal article
- editorial
- Published by Elsevier in Leukemia Research
- Vol. 19 (7) , 429-431
- https://doi.org/10.1016/0145-2126(95)00003-7
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Regrowth resistance in cancer: why has it been largely ignored?Cell Proliferation, 1995
- Regrowth resistance in leukemia and lymphoma: The need for a new system to classify treatment failure and for new approaches to treatmentLeukemia Research, 1994
- Thymocyte apoptosis induced by p53-dependent and independent pathwaysNature, 1993
- Nuclear Overexpression of p53 Protein in Transitional Cell Bladder Carcinoma: A Marker for Disease ProgressionJNCI Journal of the National Cancer Institute, 1993
- Small Subgroup of Aggressive, Highly Proliferative Prostatic Carcinomas Defined by p53 AccumulationJNCI Journal of the National Cancer Institute, 1992
- p53 Mutations, Another Breast Cancer Prognostic FactorJNCI Journal of the National Cancer Institute, 1992
- Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patientsLeukemia Research, 1991
- Unknotting the Complexities of Multidrug Resistance: The Involvement of DNA Topoisomerases in Drug Action and ResistanceJNCI Journal of the National Cancer Institute, 1989
- Prediction of Relapse or Survival in Patients with Node-Negative Breast Cancer by DNA Flow CytometryNew England Journal of Medicine, 1989
- Isolation and expression of a complementary DNA that confers multidrug resistanceNature, 1986